Rahul Vohra, MD
Physical Medicine & Rehabilitation · Flowood, MSNPI 1902991219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.3% of the total. That places this record below the midpoint for physical medicine & rehabilitation clinicians in MS, where the typical reported total is $1,133.
Across 54 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$291
- Piramal Critical Care$72
- Merz Pharmaceuticals, LLC$71
- Eisai Inc.$66
- Biohaven Pharmaceutical Holding Company Ltd.$55
- Scilex Pharmaceuticals Inc.$51
- plus $324 from 13 others
What the payments were for
- Food & beverage$929100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $291 |
| Piramal Critical Care | 4 | $72 |
| Merz Pharmaceuticals, LLC | 2 | $71 |
| Eisai Inc. | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Scilex Pharmaceuticals Inc. | 4 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Amgen | 2 | $34 |
| Medline Industries LP | 2 | $27 |
| Lundbeck LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$929 in reported general payments places this provider in the 40th percentile of 21 physical medicine & rehabilitation providers in Mississippi.
See all physical medicine & rehabilitation providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 25 | $184 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $164 |
| Tizanidine Hcl | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Flowood
- Michael WinkelmanFlowood$2K
- David CollippFlowood$2K
- Philip BlountJackson$103K
- Samuel PolkSouthaven$6K
- Parker BellHattiesburg$5K
- Joshua TuckerPascagoula$5K
- Devin WellsOxford$2K
- Barbara BarnardHattiesburg$2K
- Jennifer May VillacortaJackson$1K
- Hyung KimJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.